NEW YORK – Boston Partners, previously known as Robeco Investment Management, Inc., has crossed a significant threshold in its holdings of Hiscox (LON:) Ltd, a Bermuda-based international insurer. On November 21, 2024, Boston Partners’ voting rights in Hiscox reached 5.298%, amounting to 18,007,548 shares, according to a regulatory filing with the London Stock Exchange (LON:).
The notification, following the standard form TR-1 for major holdings, was made public on November 26, 2024, after Hiscox Ltd was informed of the change on November 25. Boston Partners’ acquisition marks a notable adjustment in the share distribution of the insurer, which operates in a competitive global market.
The shares in question carry direct voting rights, with no financial instruments involved that would confer additional voting rights. This suggests a straightforward equity holding rather than a more complex financial arrangement. Boston Partners is under the ultimate control of ORIX Corporation, which also reflects the 5.298% voting rights ownership.
The London Stock Exchange’s news service, RNS, confirmed the details of the transaction. RNS is recognized by the Financial Conduct Authority in the UK to disseminate primary information legally.
This development could be of interest to investors and market watchers, as changes in significant shareholdings can influence company strategies and investor confidence. Hiscox Ltd has not provided any additional information regarding the implications of this new ownership stake.
The transaction was completed in Boston, MA, USA, and underscores the dynamic nature of shareholding in the international insurance market. The disclosure of this information aligns with regulatory requirements intended to maintain transparency in the financial markets.
This report is based on a press release statement and aims to present the facts of the shareholding change without any additional analysis or speculation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
